Sodium–Glucose Cotransporter 2 Inhibitor Treatment and Risk of Atrial Fibrillation: Scandinavian Cohort Study
Authors:
- 12 December 2022
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 46 (2) , 351-360
Abstract
OBJECTIVE: To assess the association between use of sodium–glucose cotransporter 2 (SGLT2) inhibitors and the risk of new-onset atrial fibrillation (AF) in routine clinical practice. RESEARCH DESIGN AND METHODS: We used nationwide registers in Denmark, Norway, and Sweden from 2013 to 2018 in order to include patients without a history of AF who were newly prescribed an SGLT2 inhibitor or an active comparator (glucagon-like peptide 1 [GLP-1] receptor agonist). We performed a cohort study to assess new-onset AF in intention-to-treat analyses using Cox regression, adjusted for baseline covariates with propensity score weighting. RESULTS: We identified 79,343 new users of SGLT2 inhibitors (59.2% dapagliflozin, 40.0% empagliflozin, 0.8% canagliflozin, <0.1% ertugliflozin) and 57,613 new users of GLP-1 receptor agonists. Mean age of the study cohort was 61 years and 60% were men. The adjusted incidence rate of new-onset AF was 8.6 per 1,000 person-years for new users of SGLT2 inhibitors compared with 10.0 per 1,000 person-years for new users of GLP-1 receptor agonists. The adjusted hazard ratio (aHR) was 0.89 (95% CI 0.81–0.96), and the rate difference was 1.4 fewer events per 1,000 person-years (95% CI 0.6–2.1). Using an as-treated exposure definition, the aHR for new-onset AF was 0.87 (95% CI 0.76–0.99). No statistically significant heterogeneity of the aHRs was observed between subgroups of patients with and without a history of heart failure or major cardiovascular disease. CONCLUSIONS: In this cohort study using nationwide data from three countries, use of SGLT2 inhibitors, compared with GLP-1 receptor agonists, was associated with a modestly reduced risk of new-onset AF.Keywords
All Related Versions
Funding Information
- strategic research
- Novo Nordisk
- Karolinska Institutet
- the Swedish Research Council, the Swedish Heart-Lung Foundation, the Swedish Diabetes Foundation
This publication has 41 references indexed in Scilit:
- Global epidemiology of atrial fibrillationNature Reviews Cardiology, 2014
- Conduction and refractory disorders in the diabetic atriumAmerican Journal of Physiology-Heart and Circulatory Physiology, 2012
- Meta-Analysis of Cohort and Case–Control Studies of Type 2 Diabetes Mellitus and Risk of Atrial FibrillationThe American Journal of Cardiology, 2011
- External review and validation of the Swedish national inpatient registerBMC Public Health, 2011
- An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational StudiesMultivariate Behavioral Research, 2011
- Atrial fibrillation in the Malmö diet and cancer study: a study of occurrence, risk factors and diagnostic validityEuropean Journal of Epidemiology, 2009
- Independent Contribution of Diabetes to Increased Prevalence and Incidence of Atrial FibrillationDiabetes Care, 2009
- Multiple imputation: review of theory, implementation and softwareStatistics in Medicine, 2007
- Estimating and Using Propensity Scores with Partially Missing DataJournal of the American Statistical Association, 2000
- Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates 11Reprints are not available.The American Journal of Cardiology, 1998